NEW YORK (GenomeWeb) — ArcherDx announced today that it has signed an agreement to comarket Genosity's line of consulting and laboratory software services for genomic research.
According to Boulder, Colorado-based ArcherDx, the deal covers genomic test development services such as assay and bioinformatics design assistance, validation planning and execution services, variant interpretation support, and revenue cycle management optimization. Included under the agreement are Genosity's Genome Explorer platform, which will be integrated into ArcherDx's Archer Analysis Unlimited bioinformatics pipeline to add computational analysis and result reporting for next-generation sequencing-based panels; its Laboratory Information Management System for NGS workflows; and its Cortex application for population-level analysis and cohort identification.
Financial terms were not disclosed.
Iselin, New Jersey-based Genosity has "developed a compelling and complementary suite of services that will enable our clients to quickly and efficiently implement high-quality genomic and genetic tests that can have a profound impact on patient care," ArcherDx Cofounder and CEO Jason Myers said in a statement.
In January, ArcherDx acquired genetic carrier screening firm Baby Genes, and last year the company inked companion diagnostic assay development deals with Merck KGaA and Celgene, as well as an immune repertoire sequencing services pact with Ambry Genetics.